Claims

1. A compound represented by formula I, a ~~prodrug,~~ *N*-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof;



formula (I)

wherein

each X independently is C or N;

R_1 is H;

R_2 is selected from the group consisting of Br and Cl;

R_3 is $-(CR_6R_7)_n-R_8$;

R_4 is selected from the group consisting of ~~H,~~ C_3-C_7cycloalkyl, C_2-C_{10} alkenyl, ~~$-(CR_6R_7)_n-R_8$;~~ ~~$-CH_2$-p-Fluorophenyl,~~ CH_2CF_3 and $-SO_2CH_3$;

R_5 is present where X is C, whereby each R_5 is selected, each independently, from the group consisting of H, C_1-C_6alkyl, C_1-C_6alkoxy, halogen, and CN;

R_5 is absent where X is N;

R_6 and R_7 are each independently chosen from H and C_1-C_{10} alkyl, C_3-C_7cycloalkyl; or R_6 and R_7 taken together form a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O.

R_8 is selected from the group consisting of H, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7cycloalkyl, $NR_6SO_2R_6$, $SO_2NR_6R_7$, $NR_6SO_2C_3$-C_7cycloalkyl, CN, NR_6R_7, COOH, $COOR_6$, $CONR_6R_7$, $OCOC_1$-C_6alkyl, $CONR_6SO_2R_7$, CONH-R_6-SO_2R_7 , CONH-R_6-$SO_2NR_6R_7CONR_6SO_2NR_6R_7$, phtalimido or a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

n is an integer having a value from 1 to 6;

~~2. A compound according to claim 1 wherein~~

~~R_4 is selected from the group consisting of H, C_3-C_7cycloalkyl, C_2-C_{10} alkenyl, and $-SO_2CH_3$;~~

~~R_6 and R_7 are each independently chosen from H and C_1-C_{10} alkyl; or R_6 and R_7 taken together form a 5 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group N, S, O.~~

~~R_8 is selected from the group consisting of H, OH, CF_3, CHF_2, F, SO_2CH_3, SO_2C_3-C_7cycloalkyl, $NR_6SO_2R_6$, $SO_2NR_6R_7$, $NR_6SO_2C_3$-C_7cycloalkyl, CN, NR_6R_7.~~

~~3~~2. A compound according to claim 1 ~~or 2~~ wherein R_2 is Br.

~~4~~3. A compound according to claim 1 ~~or 2~~ wherein R_2 is Cl.

~~5~~4. A compound according to any one of the preceding claims, wherein R_6 and R_7 are H.

~~6~~5. A compound according to any one of the preceding claims, wherein n is 2-4.

~~7~~6. A compound according to any one of the preceding claims, wherein R_8 is selected from the group consisting of F, CN, OH, CF_3 and SO_2CH_3.

~~8~~7. A compound according to any one of the preceding claims, wherein R_8 is selected from the group consisting of F, CN, OH, and SO_2CH_3.

~~9~~8. A compound according to any one of the preceding claims, wherein R_4 is C_3-C_7cycloalkyl or CH_2CF_3.

~~10~~9. A compound according to any one of the preceding claims, wherein R_4 is cyclopropyl or CH_2CF_3.

~~11~~10. A compound according to any one of the preceding claims, wherein one X is N and the other X's are C.

~~12. A compound according to claim 11, wherein the N is in *para* position to N-R_4.~~

~~13. A compound according to any one of the preceding claims, wherein at most one R_5 is selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, halogen, and CN.~~

~~14. A compound according to any one of the preceding claims, wherein all R_5 are H.~~

~~15. A compound according to claim 1, wherein R_2 is Cl; one X is N and the other X's are C, wherein the N is in *para* position to N-R_4, and R_4 is cyclopropyl or CH_2CF_3.~~

11. A compound according to claim 1 wherein the compound is



or a N-oxide, addition salt, quaternary amine, or metal complex thereof.

12. The compound as claimed in claim 11 wherein the compound is



~~16~~13. A compound as claimed in any one of claims 1 to ~~15~~ 12 for use as a medicine.

~~17~~14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to ~~15~~12.

~~18~~15. A process for preparing a pharmaceutical composition as claimed in claim ~~17~~14, said process comprising ~~intimately~~ mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound as claimed in any one of claims 1 to ~~14~~12.

~~19~~16. A compound as claimed in any of claims 1 to ~~15~~ 12 for use as a medicament for inhibiting RSV replication.

~~20~~17. The use of a compound as claimed in any of claims 1 to ~~15~~ 12 for the manufacture of a medicament for inhibiting RSV replication.

~~21. A process for preparing a compound as claimed in any of the claims 1 to 15, said process comprising coupling a fragment A or B with a fragment C in accordance with scheme 1 presented in the description, resulting in derivatives of formula (I).~~